Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Clears GSK’s Requip XL For Parkinson’s

This article was originally published in The Pink Sheet Daily

Executive Summary

Once-daily version is designed to battle generic competitors.

You may also be interested in...

Generic Requip Cleared For RLS

Teva, Mylan, Roxane and Par will market ropinirole for Restless Legs Syndrome; Parkinson's patent expires this month, too.

Requip XL User Fee Date Pushed Back To Second Quarter

FDA needs additional time to review food effect data from GlaxoSmithKline for the once-daily Parkinson's treatment.

GSK Plans Next-Generation Restless Legs Treatment Filing In Q3 2008

U.K. drug maker also is planning to initiate a Phase III program evaluating GSK 1838262 for migraine prophylaxis.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts